 Home > Active Ingredient News > Drugs Articles > Suoyuan Biotech's "first-in-class" new drug successfully achieved overseas authorization

Suoyuan Biotech's "first-in-class" new drug successfully achieved overseas authorization

 Last Update: 2021-04-23
 Source: Internet
 Author: User

Tags

gene

crestor drug class

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On April 14, Suoyuan Biopharmaceuticals and Rumpus Therapeutics/Aytu Biopharma signed a global license agreement for the development of DB102 (enzastaurin) for the treatment of vascular Ehlers-Danglos syndrome (vEDS) and other rare genetic diseases.

According to the agreement, Aytu BioPharma will be responsible for the clinical development and commercialization of DB102 for this rare disease, and will pay Suoyuan Biotech a milestone and sales commission of US$100 million.
(Note: Aytu Biopharma has officially acquired Rumpus Therapeutics)

vEDS is a rare genetic disease and a severe subtype of Ehlers-Danlos syndrome.

DB102 was originally developed by Eli Lilly and Company for the first-line treatment of newly-treated high-risk diffuse large B-cell lymphoma (DLBCL) and glioblastoma (GBM).

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.